Anyone interview yet for Sparsentan?



Car allowance (Car Data decides by location) up to $1,100.00 (no gas card or mileage).
IC uncapped and the target is $62k.
Recruiter wouldn't divulge the base pay range.
No sign on bonus.
2,500 RSUs (strike price on DOH) with a four-year vesting schedule.
Offers in late May depending on FDA review and acceptance of the first IgA / NDA submission.
ESPP is at a 15% discount with a six month enrollment.
Adding 55 reps for a total of 72 in Nephrology.
Training dates are 6/13/22 and 6/27/22.
NSM and launch on 7/25/22 in San Diego, CA.
Interview process is three interviews (1 - hiring manager, 2 (panel) hiring manager, head of sales, and HR, 3 pending).

There isn't a backup plan if the first drug indication (IgA) isn't approved this year. They are counting on the second indication/approval (FSGS) to keep everyone afloat if the first indication / approval is delayed or not approved.

The scary part is the unknown acceptance of the NDA. Also, the company expects BOTH indications to be block blusters in a Rare Disease space. Many of the current reps feel that the company is hiring too many reps for a rare disease indication.
 
Car allowance (Car Data decides by location) up to $1,100.00 (no gas card or mileage).
IC uncapped and the target is $62k.
Recruiter wouldn't divulge the base pay range.
No sign on bonus.
2,500 RSUs (strike price on DOH) with a four-year vesting schedule.
Offers in late May depending on FDA review and acceptance of the first IgA / NDA submission.
ESPP is at a 15% discount with a six month enrollment.
Adding 55 reps for a total of 72 in Nephrology.
Training dates are 6/13/22 and 6/27/22.
NSM and launch on 7/25/22 in San Diego, CA.
Interview process is three interviews (1 - hiring manager, 2 (panel) hiring manager, head of sales, and HR, 3 pending).

There isn't a backup plan if the first drug indication (IgA) isn't approved this year. They are counting on the second indication/approval (FSGS) to keep everyone afloat if the first indication / approval is delayed or not approved.

The scary part is the unknown acceptance of the NDA. Also, the company expects BOTH indications to be block blusters in a Rare Disease space. Many of the current reps feel that the company is hiring too many reps for a rare disease indication.

With so many jerks on Cafepharma, thank you so much for the honest information to help others. Truly appreciate it.
 
No gas car or mileage?
 


Write your reply...